Special Issue

Application of Genetically Engineered Plant Viruses

Message from the Guest Editor

Plant viruses seriously affect crop cultivation and agricultural production worldwide. They are not always a threat but can be friends. Infectious clones of many plant viruses have been constructed and modified through genetic engineering for the study of viral pathogenesis. Attenuated plant viruses can be used as vaccines for crop protection. Viral vectors engineered from infectious clones of plant viruses are effective tools for overexpressing genes of interest in plants for human/animal disease treatment and health. Plant viral vectors have also been exploited to knock down plant gene expression through virus-induced gene silencing. In this Special Issue, we welcome a wide range of articles, including original research, short communications, and reviews, that focus on the application of genetically engineered plant viruses in agriculture, medicine, human/animal health, and other fields. Your research achievements will significantly contribute to enhancing our understanding of this field. We look forward to receiving your submissions for this Special Issue.

Guest Editor

Prof. Dr. Tsung-Chi Chen

Department of Medical Laboratory Science and Biotechnology, Asia University, Taichung City, Taiwan

Deadline for manuscript submissions

31 December 2025



Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/209847

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/ viruses





Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).

